Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Hands holding a glass lung

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing treatment response in melanoma and NSCLC patients receiving immune checkpoint inhibitors.

The results indicate that iRECIST is better suited for capturing atypical treatment responses to immunotherapies, especially in patients experiencing pseudoprogression. iRECIST could thus contribute to a more accurate evaluation of treatment response and improved immunotherapy outcomes.

Read more about the study here.

Related Resources

Related Resources

RACOON FADEN: Pioneering Early Detection of Adenomyosis – Insights from Prof. Mechsner (Charité Berlin) and Prof. May (University Hospital Erlangen)

Adenomyosis is a gynecological condition of the uterus and a form of endometriosis. Approximately 10 percent of women of reproductive age are affected…

Virtual examination of human lungs on a modern interface screen

Early Detection of Treatment Response in Lung Cancer Using Delta-Radiomics Features

The study conducted by Heidelberg University Hospital investigates the use of diffusion-weighted MRI (DWI) to predict early treatment outcomes in…

The image serves as a graphical abstract, displaying visuals from the study, ranging from MRI scans to the analysis of delta-radiomics texture features

Heidelberg University Hospital: Delta-Radiomics Features from ADC Maps as Early Predictors of Treatment Success in Lung Cancer Therapy

In this prospective study conducted by Heidelberg University Hospital, researchers investigated whether changes in radiomic features from…